Qualone Withdrawal & Recovery: Evidence and Safety

Novel Sedative & Qualone Withdrawal & Recovery

Emergency warning: Seizure, delirium, severe confusion, hallucinations, inability to wake, abnormal breathing, collapse, or dangerous agitation after stopping or using a sedative-hypnotic requires urgent medical evaluation.

Quick answer

Methaqualone is a dependence-producing sedative-hypnotic with historical evidence of a potentially dangerous withdrawal syndrome, including seizures. (Inger JA, 2023; Faught E, 1986).

Modern “qualone” research chemicals such as 2-methoxyqualone, dicloqualone and other clandestine quinazolinones are much less studied in humans.

That distinction matters:

• methaqualone provides proof that the chemical family can produce sedative dependence;
• methaqualone withdrawal cannot be assumed to map perfectly onto every modern analogue;
• there is no validated self-taper or drug-equivalence table for modern qualone RCs.

Why these drugs are not just benzodiazepines

Methaqualone is a GABA-A receptor modulator, but it does not bind at the classic benzodiazepine site. (Hammer H, 2015; Chojnacka W, 2024).

Modern structural and functional studies place methaqualone at transmembrane GABA-A receptor interfaces overlapping more closely with sites used by some anesthetic modulators.

That means a shared “GABAergic sedative” label does not create a benzodiazepine-equivalence conversion.

Dependence

Historical methaqualone experience documented:

• tolerance;
• compulsive use;
• escalating consumption;
• physical dependence;
• withdrawal after cessation. Inger JA, 2023.

The 2023 DARK Classics review describes methaqualone as a drug whose widespread recreational use exposed substantial overdose and dependence liability.

Withdrawal

Historical reports describe withdrawal symptoms including:

• anxiety;
• insomnia;
• tremor;
• agitation;
• autonomic symptoms;
• perceptual disturbance;
• seizures. (Faught E, 1986; Inger JA, 2023).

A published neurologic case documented myoclonic and tonic-clonic seizures during methaqualone withdrawal, with EEG abnormalities that resolved with the withdrawal state.

The strongest practical conclusion is therefore:

abrupt cessation after substantial repeated methaqualone-type sedative exposure should not be assumed medically benign.

Seizure risk

Seizure risk is especially important because the parent drug has both sedative and anticonvulsant properties. Faught E, 1986.

As with other CNS depressants, neuroadaptation during repeated exposure can create instability when the drug is abruptly removed.

The evidence is too limited to estimate the probability of seizure for any individual user.

Modern qualone analogues

Modern RC analogues may include:

• 2-methoxyqualone;
• dicloqualone;
• etaqualone;
• mebroqualone;
• methylmethaqualone;
• other quinazolinone derivatives. Yang H, 2023.

For many of these compounds, available data are primarily:

• receptor pharmacology;
• analytical chemistry;
• forensic detection;
• scattered case reports;
• community reports.

Direct prospective withdrawal evidence is usually absent.

What can be inferred safely?

Reasonable class inference:

• sedative impairment is plausible;
• tolerance and dependence are possible;
• abrupt cessation after heavy repeated exposure may be risky. Inger JA, 2023.

Unsafe overreach:

• assuming every analogue has methaqualone's exact potency;
• assigning a benzodiazepine conversion;
• publishing a universal taper;
• assuming a specific withdrawal onset/peak;
• treating online reports as clinical evidence.

Treatment evidence is extremely weak

A Cochrane review of methaqualone-dependence treatment searched for randomized and quasi-randomized trials and found no eligible controlled studies. McCarthy G, 2005.

Therefore, there is no evidence-based methaqualone-specific medication protocol that can be presented as standard of care.

Clinical management must instead be individualized around:

• seizure risk;
• delirium/agitation;
• vital signs;
• polysubstance use;
• psychiatric symptoms;
• duration/intensity of exposure.

Do not self-convert to benzodiazepines

It is tempting to treat any GABAergic sedative as if it had a diazepam-equivalent dose. Hammer H, 2015.

That is not scientifically justified here.

Differences in:

• binding site;
• receptor subtype activity;
• half-life;
• active metabolites;
• product purity;
• dose measurement

make a conversion table especially unreliable.

Polysubstance risk

Sedative withdrawal and intoxication become harder to interpret when the person also uses:

• alcohol;
• benzodiazepines;
• GHB/GBL;
• opioids;
• gabapentinoids;
• sedating antihistamines. Doyno CR, 2021.

Alcohol or benzodiazepine withdrawal may be the dominant life-threatening syndrome even when the person believes the main problem is an RC qualone.

Recovery after the acute phase

Recovery may include:

• sleep disruption;
• anxiety;
• low mood;
• craving;
• fear of withdrawal recurrence;
• cognitive slowing;
• rebuilding normal routines without sedatives. McCarthy G, 2005.

Because long-term modern-analogue data are sparse, there is no validated post-acute recovery timeline.

Use disorder versus dependence

Physical dependence is not identical to a sedative use disorder. Doyno CR, 2021.

Warning signs of a use disorder include:

• inability to cut down;
• hazardous intoxication;
• repeated blackouts or injuries;
• escalating use despite harm;
• neglect of work or relationships;
• craving;
• substantial time spent obtaining, using or recovering.

When supervised withdrawal deserves strong consideration

Medical assessment is especially important with:

• prior withdrawal seizure;
• daily/high-frequency sedative use;
• uncertain product strength;
• multiple CNS depressants;
• history of delirium;
• pregnancy;
• serious respiratory disease;
• inability to remain safe at home. (Doyno CR, 2021; Faught E, 1986).

Evidence ledger

For U.S. treatment referrals, SAMHSA’s National Helpline, 1-800-662-HELP (4357), is available 24 hours a day. FindTreatment.gov lists treatment services. Referral services do not replace emergency care.

Bottom line

The parent compound methaqualone proves that qualone-type sedatives can produce serious dependence and medically important withdrawal.

What the evidence does not justify is pretending modern analogues have a known benzodiazepine conversion, a safe DIY taper, or a predictable withdrawal clock.

For this class, the safest high-quality guidance is to preserve the historical seizure warning, separate parent-drug evidence from analogue inference, and recommend individualized medical assessment when repeated heavy sedative exposure suggests physical dependence.

Related evidence

• Novel Sedatives & Qualone Analogues
• 2-Methoxyqualone
• Dicloqualone
• Benzodiazepine & Z-Drug Withdrawal & Recovery